Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim  
2022, Cilt 52, Sayı 3, Sayfa(lar) 208-215
[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Evaluation of Architect® EBV Antibody Panel Results and EBV Diagnostic Algorithms
Özgür Appak1, Abdurrahman Gülmez2, Arzu Sayıner1
1Dokuz Eylül Üniversitesi, Tıp Fakültesi, Tıbbi Mikrobiyoloji Anabilim Dalı, Tıbbi Viroloji Bilim Dalı, İzmir, Türkiye
2İstanbul Başakşehir Çam ve Sakura Şehir Hastanesi, Tıbbi Mikrobiyoloji, İstanbul, Türkiye
Keywords: EBV, serology, algorithm

Objective: In the study, it is aimed to analyze the results of EBV-specific VCA IgM, VCA IgG and EBNA-1 IgG antibodies, to obtain seroepidemiological data and to evaluate the usability of EBV test algorithms and their effects on cost.

Methods: The test results of the patients whose EBV serology was evaluated with the Architect® (Abbott) device in the Serology Laboratory between January 2018 and December 2021 were evaluated retrospectively. The effects of two different test algorithms initiated according to the anti-VCA and anti-EBNA results were examined.

Results: During the study period, 6529 serum samples were evaluated. The EBV seropositivity rate was 86%, and the most common EBV clinical profile was ‘past infection’. Atypical EBV profile rate was 12.6%, and positivity of all three tests together and isolated VCA IgG positivity were common. While the anti-VCA (VCA IgM/VCA IgG) approach makes it unnecessary to use the EBNA-1 IgG test in 14.8% of all cases, the anti-EBNA (EBNA-1 IgG) approach makes it unnecessary to use VCA IgM-VCA IgG tests in 76.7% of all cases. It was determined that isolated EBNA-1 IgG cases in the anti-VCA approach and reactivation cases in the anti-EBNA approach could be misinterpreted.

Conclusion: The seropositivity rate determined in our study is consistent with the data of our country. The EBNA- 1 IgG approach reduces testing costs by approximately 50%, and it has been concluded that this algorithm can be applied in immunocompetent individuals.


[ Türkçe Özet ] [ PDF ] [ Benzer Makaleler ]
Ana Sayfa | Dergi Hakkında | Yayın Kurulu | Telif Hakkı Devir Formu | İçindekiler | Arşiv | Yayın Arama | Yazarlara Bilgi | İletişim